Please try another search
OmniComm Systems, Inc., a healthcare technology company, provides Web-based electronic data capture (EDC), and eClinical software and services for pharmaceutical and biotechnology companies, clinical research organizations (CROs), and other clinical trial sponsors worldwide. It offers TrialMaster, which allows organizations conducting clinical trials to collect and manage the data over the Internet; TrialOne Phase I Clinic Automation, a software application suite that provides clinical trial site sponsors, study investigators, and study monitors with various tools to conduct the Phase I clinic operation; and IRTMaster, which offers interactive response technology in support of the randomization process in clinical trials. The company also provides eClinical Suite that comprises a set of tools for collecting and managing clinical data, including EDC for real-time entry and double data entry (DDE) for entry from paper originals; and Promasys, a clinical trial data management system for DDE and EDC, which is primarily used at research institutions for investigator-initiated trials. In addition, it offers Acuity, a clinical data aggregation and analytics platform that provides actionable insights into quality, risk, and performance of various aspects of clinical trials in real time. Further, the company provides consulting and professional services, such as project management, clinical services, training, custom configuration, system integration, standard operating procedures and implementation assistance, installation, and validation services, as well as application hosting and related support services. It sells its products through a direct sales force and relationships with CRO partners, as well as through co-marketing agreements with vendor and channel partners. OmniComm Systems, Inc. was founded in 1996 and is headquartered in Fort Lauderdale, Florida. As of September 18, 2019, OmniComm Systems, Inc. operates as a subsidiary of Anju Software, Inc.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review